{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007075","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.494223+00:00","generated_at":"2026-05-16T23:55:38.848654+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M","bullets":["Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.","Cash, cash equivalents and investments $99.1M as of Sep 30, 2025; runway into Q3 2026.","Phase 2 B-SUPREME trial of pevifoscorvir sodium (CAM-E) for chronic HBV enrolled first patient Aug 2025; interim data 2026.","Preclinical combo data with ALG-055009 (THR-β) and incretin RAs showed synergistic weight loss; out-licensing discussions ongoing.","R&D expenses rose to $23.9M (from $16.8M) driven by Phase 2 costs; G&A $5.2M (from $4.6M) due to legal."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007075","json":"https://secwatch.observer/filing/0001171843-25-007075.json","markdown":"https://secwatch.observer/filing/0001171843-25-007075.md","text":"https://secwatch.observer/filing/0001171843-25-007075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/0001171843-25-007075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/f8k_110525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:55:38.848654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}